Drug Therapy for Borderline Personality Disorder Evaluated
While no drugs are currently approved for the treatment of BPD, nearly all patients with this condition receive at least 1 psychotropic medication.
Psychosis
Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia
The Food and Drug Administration has approved Invega Hafyera™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting atypical antipsychotic that is administered as a gluteal intramuscular injection by a health care professional. Prior to initiating treatment with Invega Hafyera, patients must have been adequately treated…
Application for Long-Acting Schizophrenia Treatment Accepted for Review
Patients treated with the investigational subcutaneous risperidone injection experienced a statistically significant delay in the time to relapse.
Lyme Disease Tied to Higher Risk for Psychiatric Conditions, Suicide
Risk particularly heightened in the six months following diagnosis
Important Clozapine REMS Program Changes Announced
According to the FDA, prescribers and pharmacies must be re-certified in the Clozapine REMS program by November 15, 2021 to continue to prescribe or dispense clozapine.
Relapse Risk for Psychosis in Dementia Lower With Continued Pimavanserin
Findings seen in double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy
Lybalvi Approved for Schizophrenia, Bipolar I Disorder
The approval was based on data from 27 clinical studies, including the phase 3 ENLIGHTEN-1 and ENLIGHTEN-2 studies.
Novel Glycine Transporter Inhibitor Gets Breakthrough Tx Status for Cognitive Impairment With Schizophrenia
The designation is based on results from a phase 2 trial that evaluated the efficacy and safety of 4 different doses of BI 425809 orally once daily in adults with CIAS for 12 weeks.
Dexmedetomidine Oral Film Under Review for Agitation With Schizophrenia, Bipolar Disorder
In both trials, BXCL501 demonstrated statistically significant, rapid and durable improvements vs placebo across multiple agitation scales.
FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis
The sNDA submission was supported by data from the pivotal phase 3 HARMONY study.
